Rafael Holdings (Rafael Holdings) FCF Margin % : -3,719.12% (As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Rafael Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Rafael Holdings's Free Cash Flow for the three months ended in Jan. 2024 was $-2.53 Mil. Rafael Holdings's Revenue for the three months ended in Jan. 2024 was $0.07 Mil. Therefore, Rafael Holdings's FCF Margin % for the quarter that ended in Jan. 2024 was -3,719.12%.

As of today, Rafael Holdings's current FCF Yield % is -19.36%.

The historical rank and industry rank for Rafael Holdings's FCF Margin % or its related term are showing as below:

RFL' s FCF Margin % Range Over the Past 10 Years
Min: -6361.22 Med: -88.76 Max: -26.5
Current: -2699.64

During the past 8 years, the highest FCF Margin % of Rafael Holdings was -26.50%. The lowest was -6361.22%. And the median was -88.76%.

RFL's FCF Margin % is ranked worse than
99.33% of 1798 companies
in the Real Estate industry
Industry Median: 5.205 vs RFL: -2699.64

Rafael Holdings FCF Margin % Historical Data

The historical data trend for Rafael Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rafael Holdings FCF Margin % Chart

Rafael Holdings Annual Data

Trend

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

FCF Margin %

Get a 7-Day Free Trial

-71.61

-105.91

-1,970.95

-6,361.22

-3,901.79

Rafael Holdings Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
FCF Margin %	Get a 7-Day Free Trial															-7,920.00	-1,850.70	-2,129.41	-3,136.76	-3,719.12

Competitive Comparison of Rafael Holdings's FCF Margin %

For the Real Estate Services subindustry, Rafael Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rafael Holdings's FCF Margin % Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Rafael Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Rafael Holdings's FCF Margin % falls into.

Rafael Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Rafael Holdings's FCF Margin for the fiscal year that ended in Jul. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jul. 2023 )	/	Revenue (A: Jul. 2023 )
	=	-10.886	/	0.279
	=	-3,901.79 %

Rafael Holdings's FCF Margin for the quarter that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-2.529	/	0.068
	=	-3,719.12 %

Rafael Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Rafael Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rafael Holdings (Rafael Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

520 Broad Street, Newark, NJ, USA, 07102

Website

https://www.rafaelholdings.com

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Executives

I9 Plus, Llc	10 percent owner	153 BOOTH AVE, ENGLEWOOD NJ 07631
Howard S Jonas	director
Mary Margaret Huizinga	officer: Chief Devel. & Medical Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Ashok D Marin	officer: Chief Legal Officer	C/O LIPOSCIENCE, INC., 2500 SUMNER BOULEVARD, RALEIGH NC 27616
Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Shannon Thyme Klinger	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Ameet Mallik	officer: CHIEF EXECUTIVE OFFICER	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
William Conkling	officer: Chief Commercial Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Rachel Jonas	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Boris C Pasche	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Michael J Weiss	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
Stephen M Greenberg	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
David Polinsky	officer: Chief Financial Officer	90 BOOTH AVENUE, ENGLEWOOD NJ 07631
Menachem Ash	director, officer: President	C/O IDT CORPORATION, 520 BROAD STREET, NEWARK NJ 07102